{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:37:28Z","timestamp":1793637448967,"version":"4.5.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20355"],"award-info":[{"award-number":["U21A20355"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Medical Research Project for Technological Innovation in Chongqing Health Commission & Chongqing Science and Technology Commission","award":["2025GGXM004"],"award-info":[{"award-number":["2025GGXM004"]}]},{"name":"Chongqing Outstanding Youth Science Fund project","award":["CSTB2023NSCQ-JQX0028"],"award-info":[{"award-number":["CSTB2023NSCQ-JQX0028"]}]},{"name":"Key Project of Special Technological Innovation and Application Development in Chongqing","award":["CSTB2024TIAD-KPX0039"],"award-info":[{"award-number":["CSTB2024TIAD-KPX0039"]}]},{"name":"Key Project of Special Technological Innovation and Application Development in Chongqing","award":["CSTB2025TIAD-KPX0098"],"award-info":[{"award-number":["CSTB2025TIAD-KPX0098"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40265-026-02302-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:56:45Z","timestamp":1773759405000},"page":"737-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Renin Angiotensin Aldosterone System Inhibitors on Cardiovascular Outcomes in Hypertensive Population: A Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"86","author":[{"given":"Yueming","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6445","authenticated-orcid":false,"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-4779","authenticated-orcid":false,"given":"Shumin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"2302_CR1","unstructured":"World Health Organization. Global report on hypertension 2025. 2025. https:\/\/www.who.int\/publications\/b\/81068. Accessed 3 Jan 2026."},{"key":"2302_CR2","unstructured":"World Health Organization. Global report on hypertension: the race against a silent killer. 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240081062. Accessed 3 Jan 2026."},{"key":"2302_CR3","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76:2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"key":"2302_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.gheart.2012.12.004","volume":"8","author":"SS Franklin","year":"2013","unstructured":"Franklin SS, Wong ND. Hypertension and cardiovascular disease: contributions of the Framingham heart study. Glob Heart. 2013;8:49\u201357. https:\/\/doi.org\/10.1016\/j.gheart.2012.12.004.","journal-title":"Glob Heart"},{"key":"2302_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8.","journal-title":"Lancet"},{"key":"2302_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. https:\/\/doi.org\/10.1136\/bmj.b1665.","journal-title":"BMJ"},{"key":"2302_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/s0140-6736(03)14739-3","volume":"362","author":"F Turnbull","year":"2003","unstructured":"Turnbull F, Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527\u201335. https:\/\/doi.org\/10.1016\/s0140-6736(03)14739-3.","journal-title":"Lancet"},{"key":"2302_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10557-012-6424-y","volume":"27","author":"TG von Lueder","year":"2013","unstructured":"von Lueder TG, Krum H. RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther. 2013;27:171\u20139. https:\/\/doi.org\/10.1007\/s10557-012-6424-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2302_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u201357. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15026.","journal-title":"Hypertension"},{"key":"2302_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41:1874\u20132071. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"key":"2302_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1464-5491.2004.01122.x","volume":"21","author":"A Siebenhofer","year":"2004","unstructured":"Siebenhofer A, Plank J, Horvath K, Berghold A, Sutton AJ, Sommer R, et al. Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabet Med. 2004;21:18\u201325. https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01122.x.","journal-title":"Diabet Med"},{"key":"2302_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004136.pub2","author":"GFM Strippoli","year":"2005","unstructured":"Strippoli GFM, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.CD004136.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2302_CR13","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(05)67814-2","volume":"366","author":"JP Casas","year":"2005","unstructured":"Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(05)67814-2.","journal-title":"Lancet"},{"key":"2302_CR14","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139. https:\/\/doi.org\/10.1056\/NEJMoa011161.","journal-title":"N Engl J Med"},{"key":"2302_CR15","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1161\/STROKEAHA.110.606764","volume":"42","author":"H Arima","year":"2011","unstructured":"Arima H, Anderson C, Omae T, Woodward M, Hata J, Murakami Y, et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the perindopril protection against recurrent stroke study (PROGRESS) trial. Stroke. 2011;42:2339\u201341. https:\/\/doi.org\/10.1161\/STROKEAHA.110.606764.","journal-title":"Stroke"},{"key":"2302_CR16","doi-asserted-by":"publisher","unstructured":"Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145\u201353. https:\/\/doi.org\/10.1056\/NEJM200001203420301","DOI":"10.1056\/NEJM200001203420301"},{"key":"2302_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/1573402115666191011111402","volume":"16","author":"G Lamirault","year":"2020","unstructured":"Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N, Hypertension NUHWGO. Resistant hypertension: novel insights. Curr Hypertens Rev. 2020;16:61\u201372. https:\/\/doi.org\/10.2174\/1573402115666191011111402.","journal-title":"Curr Hypertens Rev"},{"key":"2302_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"2302_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"2302_CR20","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"key":"2302_CR21","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2110956.","journal-title":"N Engl J Med"},{"key":"2302_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJV McMurray","year":"2016","unstructured":"McMurray JJV, Krum H, Abraham WT, Dickstein K, K\u00f8ber LV, Desai AS, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med. 2016;374:1521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1514859.","journal-title":"N Engl J Med"},{"key":"2302_CR23","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"H-H Parving","year":"2012","unstructured":"Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1208799.","journal-title":"N Engl J Med"},{"key":"2302_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41371-018-0138-y","volume":"33","author":"C Dimou","year":"2019","unstructured":"Dimou C, Antza C, Akrivos E, Doundoulakis I, Stabouli S, Haidich AB, et al. A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension. J Hum Hypertens. 2019;33:188\u2013201. https:\/\/doi.org\/10.1038\/s41371-018-0138-y.","journal-title":"J Hum Hypertens"},{"key":"2302_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijcard.2016.04.132","volume":"217","author":"F Ricci","year":"2016","unstructured":"Ricci F, Di Castelnuovo A, Savarese G, Perrone Filardi P, De Caterina R. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - a network meta-analysis. Int J Cardiol. 2016;217:128\u201334. https:\/\/doi.org\/10.1016\/j.ijcard.2016.04.132.","journal-title":"Int J Cardiol"},{"key":"2302_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012570.pub2","author":"GM Wang","year":"2025","unstructured":"Wang GM, Li LJ, Fan L, Xu M, Tang WL, Wright JM. Renin inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev. 2025. https:\/\/doi.org\/10.1002\/14651858.CD012570.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2302_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102615","volume":"49","author":"K Pamporis","year":"2024","unstructured":"Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E, et al. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Curr Probl Cardiol. 2024;49:102615. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102615.","journal-title":"Curr Probl Cardiol"},{"key":"2302_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","volume":"3","author":"J Wei","year":"2020","unstructured":"Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw Open. 2020;3:e1921618. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.21618.","journal-title":"JAMA Netw Open"},{"key":"2302_CR29","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40265-024-02092-7","volume":"84","author":"X Yi","year":"2024","unstructured":"Yi X, Yang S, Yang J, Chen X, Zhang A, Zeng Q, et al. Renin-angiotensin-aldosterone system modulators in adults with hypertension: a network meta-analysis of randomized controlled trials. Drugs. 2024;84:1445\u201362. https:\/\/doi.org\/10.1007\/s40265-024-02092-7.","journal-title":"Drugs"},{"key":"2302_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"2302_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2302_CR32","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"2302_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71:1269\u2013324. https:\/\/doi.org\/10.1161\/HYP.0000000000000066.","journal-title":"Hypertension"},{"key":"2302_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2302_CR35","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019013","volume":"41","author":"SR Shim","year":"2019","unstructured":"Shim SR, Kim S-J, Lee J, R\u00fccker G. Network meta-analysis: application and practice using R software. Epidemiol Health. 2019;41:e2019013. https:\/\/doi.org\/10.4178\/epih.e2019013.","journal-title":"Epidemiol Health"},{"key":"2302_CR36","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"2302_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11121-021-01289-6","volume":"23","author":"G Seitidis","year":"2022","unstructured":"Seitidis G, Nikolakopoulos S, Hennessy EA, Tanner-Smith EE, Mavridis D. Network meta-analysis techniques for synthesizing prevention science evidence. Prev Sci. 2022;23:415\u201324. https:\/\/doi.org\/10.1007\/s11121-021-01289-6.","journal-title":"Prev Sci"},{"key":"2302_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"key":"2302_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/ije\/dys041","volume":"41","author":"RM Turner","year":"2012","unstructured":"Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol. 2012;41:818\u201327. https:\/\/doi.org\/10.1093\/ije\/dys041.","journal-title":"Int J Epidemiol"},{"key":"2302_CR40","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1002\/sim.6001","volume":"32","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med. 2013;32:5414\u201329. https:\/\/doi.org\/10.1002\/sim.6001.","journal-title":"Stat Med"},{"key":"2302_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-35","volume":"13","author":"U Krahn","year":"2013","unstructured":"Krahn U, Binder H, K\u00f6nig J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35. https:\/\/doi.org\/10.1186\/1471-2288-13-35.","journal-title":"BMC Med Res Methodol"},{"key":"2302_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3:98\u2013110. https:\/\/doi.org\/10.1002\/jrsm.1044.","journal-title":"Res Synth Methods"},{"key":"2302_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3:161\u201376. https:\/\/doi.org\/10.1002\/jrsm.57.","journal-title":"Res Synth Methods"},{"key":"2302_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"2302_CR45","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","volume":"285","author":"LY Agodoa","year":"2001","unstructured":"Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719\u201328. https:\/\/doi.org\/10.1001\/jama.285.21.2719.","journal-title":"JAMA"},{"key":"2302_CR46","doi-asserted-by":"publisher","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981\u201397. https:\/\/doi.org\/10.1001\/jama.288.23.2981","DOI":"10.1001\/jama.288.23.2981"},{"key":"2302_CR47","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/hr.2012.125","volume":"35","author":"K Asayama","year":"2012","unstructured":"Asayama K, Ohkubo T, Metoki H, Obara T, Inoue R, Kikuya M, et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res. 2012;35:1102\u201310. https:\/\/doi.org\/10.1038\/hr.2012.125.","journal-title":"Hypertens Res"},{"key":"2302_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/s0168-8227(01)00288-1","volume":"54","author":"S Baba","year":"2001","unstructured":"Baba S. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 2001;54:191\u2013201. https:\/\/doi.org\/10.1016\/s0168-8227(01)00288-1.","journal-title":"Diabetes Res Clin Pract"},{"key":"2302_CR49","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"2302_CR50","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952\u201361. https:\/\/doi.org\/10.1056\/NEJMoa042274.","journal-title":"N Engl J Med"},{"key":"2302_CR51","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","volume":"138","author":"T Berl","year":"2003","unstructured":"Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542\u20139. https:\/\/doi.org\/10.7326\/0003-4819-138-7-200304010-00010.","journal-title":"Ann Intern Med"},{"key":"2302_CR52","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1097\/00004872-200312000-00030","volume":"21","author":"CJ Bulpitt","year":"2003","unstructured":"Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, et al. Results of the pilot study for the hypertension in the very elderly trial. J Hypertens. 2003;21:2409\u201317. https:\/\/doi.org\/10.1097\/00004872-200312000-00030.","journal-title":"J Hypertens"},{"key":"2302_CR53","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995\u20131003. https:\/\/doi.org\/10.1016\/S0140-6736(02)08089-3.","journal-title":"Lancet"},{"key":"2302_CR54","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645\u201352. https:\/\/doi.org\/10.1056\/NEJM199803053381003.","journal-title":"N Engl J Med"},{"key":"2302_CR55","doi-asserted-by":"publisher","first-page":"9R","DOI":"10.1016\/s0002-9149(98)00750-4","volume":"82","author":"RO Estacio","year":"1998","unstructured":"Estacio RO, Schrier RW. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol. 1998;82:9R-14R. https:\/\/doi.org\/10.1016\/s0002-9149(98)00750-4.","journal-title":"Am J Cardiol"},{"key":"2302_CR56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/s0895-7061(02)03017-0","volume":"15","author":"R Fogari","year":"2002","unstructured":"Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:1042\u20139. https:\/\/doi.org\/10.1016\/s0895-7061(02)03017-0.","journal-title":"Am J Hypertens"},{"key":"2302_CR57","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1097\/HJH.0000000000000154","volume":"32","author":"S Foulquier","year":"2014","unstructured":"Foulquier S, B\u00f6hm M, Schmieder R, Sleight P, Teo K, Yusuf S, et al. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a telmisartan randomised AssessmeNt study in ACE iNtolerant subjects with cardiovascular disease subanalysis. J Hypertens. 2014;32:1334\u201341. https:\/\/doi.org\/10.1097\/HJH.0000000000000154.","journal-title":"J Hypertens"},{"key":"2302_CR58","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/HJH.0000000000000837","volume":"34","author":"FD Fuchs","year":"2016","unstructured":"Fuchs FD, Scala LCN, Vilela-Martin JF, de Mello RB, Mosele F, Whelton PK, et al. Effectiveness of chlorthalidone\/amiloride versus losartan in patients with stage I hypertension: results from the PREVER-treatment randomized trial. J Hypertens. 2016;34:798\u2013806. https:\/\/doi.org\/10.1097\/HJH.0000000000000837.","journal-title":"J Hypertens"},{"key":"2302_CR59","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/s0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, Dahl\u00f6f B, Lanke J, Scherst\u00e9n B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish trial in old patients with hypertension-2 study. Lancet. 1999;354:1751\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(99)10327-1.","journal-title":"Lancet"},{"key":"2302_CR60","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/hr.2013.86","volume":"36","author":"E Imai","year":"2013","unstructured":"Imai E, Haneda M, Yamasaki T, Kobayashi F, Harada A, Ito S, et al. Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-hypertension). Hypertens Res. 2013;36:1051\u20139. https:\/\/doi.org\/10.1038\/hr.2013.86.","journal-title":"Hypertens Res"},{"key":"2302_CR61","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(04)16451-9.","journal-title":"Lancet"},{"key":"2302_CR62","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","volume":"21","author":"H Lithell","year":"2003","unstructured":"Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875\u201386. https:\/\/doi.org\/10.1097\/00004872-200305000-00011.","journal-title":"J Hypertens"},{"key":"2302_CR63","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/HJH.0b013e3282ff8864","volume":"26","author":"S L\u00fcders","year":"2008","unstructured":"L\u00fcders S, Schrader J, Berger J, Unger T, Zidek W, B\u00f6hm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German hypertension league. J Hypertens. 2008;26:1487\u201396. https:\/\/doi.org\/10.1097\/HJH.0b013e3282ff8864.","journal-title":"J Hypertens"},{"key":"2302_CR64","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1097\/HJH.0b013e328348345d","volume":"29","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649\u201359. https:\/\/doi.org\/10.1097\/HJH.0b013e328348345d.","journal-title":"J Hypertens"},{"key":"2302_CR65","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641\u201350. https:\/\/doi.org\/10.1681\/ASN.2009070737.","journal-title":"J Am Soc Nephrol"},{"issue":"B","key":"2302_CR66","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_b.2","volume":"15","author":"LA Moy\u00e9","year":"1994","unstructured":"Moy\u00e9 LA, Pfeffer MA, Wun CC, Davis BR, Geltman E, Hayes D, et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Survival and ventricular enlargement study. Eur Heart J. 1994;15(B):2\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/15.suppl_b.2.","journal-title":"Eur Heart J"},{"key":"2302_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0895-7061(99)00215-0","volume":"13","author":"T Ogihara","year":"2000","unstructured":"Ogihara T. Practitioner\u2019s trial on the efficacy of antihypertensive treatment in the elderly hypertension (the PATE-hypertension study) in Japan. Am J Hypertens. 2000;13:461\u20137. https:\/\/doi.org\/10.1016\/s0895-7061(99)00215-0.","journal-title":"Am J Hypertens"},{"key":"2302_CR68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","volume":"51","author":"T Ogihara","year":"2008","unstructured":"Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51:393\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.098475.","journal-title":"Hypertension"},{"key":"2302_CR69","doi-asserted-by":"publisher","unstructured":"Pitt B, Ahmed A, L TE, Krum H, Nicolau J, Cardoso JS, et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertens Dallas Tex 1979. 2008;52:271\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.109314","DOI":"10.1161\/HYPERTENSIONAHA.107.109314"},{"key":"2302_CR70","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","volume":"58","author":"P Ruggenenti","year":"2011","unstructured":"Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011;58:776\u201383. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.174474.","journal-title":"Hypertension"},{"key":"2302_CR71","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/eurheartj\/ehu504","volume":"36","author":"Y Sakata","year":"2015","unstructured":"Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015;36:915\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehu504.","journal-title":"Eur Heart J"},{"key":"2302_CR72","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader J, L\u00fcders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218\u201326. https:\/\/doi.org\/10.1161\/01.STR.0000166048.35740.a9.","journal-title":"Stroke"},{"key":"2302_CR73","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","volume":"8","author":"M Serenelli","year":"2020","unstructured":"Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, et al. Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8:188\u201398. https:\/\/doi.org\/10.1016\/j.jchf.2019.09.011.","journal-title":"JACC Heart Fail"},{"key":"2302_CR74","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2337\/diacare.21.4.597","volume":"21","author":"P Tatti","year":"1998","unstructured":"Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597\u2013603. https:\/\/doi.org\/10.2337\/diacare.21.4.597.","journal-title":"Diabetes Care"},{"key":"2302_CR75","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","volume":"35","author":"KK Teo","year":"2014","unstructured":"Teo KK, Pfeffer M, Mancia G, O\u2019Donnell M, Dagenais G, Diaz R, et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014;35:1743\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehu079.","journal-title":"Eur Heart J"},{"key":"2302_CR76","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1097\/HJH.0b013e3283480db9","volume":"29","author":"T Tillin","year":"2011","unstructured":"Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy candesartan trials-protect 2 study. J Hypertens. 2011;29:1457\u201362. https:\/\/doi.org\/10.1097\/HJH.0b013e3283480db9.","journal-title":"J Hypertens"},{"key":"2302_CR77","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018827","volume":"9","author":"T Tsujimoto","year":"2020","unstructured":"Tsujimoto T, Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020;9:e018827. https:\/\/doi.org\/10.1161\/JAHA.120.018827.","journal-title":"J Am Heart Assoc"},{"key":"2302_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMoa021716","volume":"348","author":"LMH Wing","year":"2003","unstructured":"Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GLR, et al. A comparison of outcomes with angiotensin-converting\u2014enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583\u201392. https:\/\/doi.org\/10.1056\/NEJMoa021716.","journal-title":"N Engl J Med"},{"key":"2302_CR79","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1291\/hypres.27.181","volume":"27","author":"Y Yui","year":"2004","unstructured":"Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan multicenter investigation for cardiovascular diseases-B (JMIC-B) randomized trial. Hypertens Res Off J Jpn Soc Hypertens. 2004;27:181\u201391. https:\/\/doi.org\/10.1291\/hypres.27.181.","journal-title":"Hypertens Res Off J Jpn Soc Hypertens."},{"key":"2302_CR80","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225\u201337. https:\/\/doi.org\/10.1056\/NEJMoa0804593.","journal-title":"N Engl J Med"},{"key":"2302_CR81","doi-asserted-by":"crossref","unstructured":"Study Group on Long-term Antihypertensive Therapy. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension\u2014the GLANT study. Hypertens Res Off J Jpn Soc Hypertens. 1995;18:235\u201344.","DOI":"10.1291\/hypres.18.235"},{"key":"2302_CR82","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713\u201320.","DOI":"10.1136\/bmj.317.7160.713"},{"key":"2302_CR83","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(03)14286-9.","journal-title":"Lancet"},{"key":"2302_CR84","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","volume":"79","author":"LM Ruilope","year":"2022","unstructured":"Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, et al. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022;79:2685\u201395. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19744.","journal-title":"Hypertension"},{"key":"2302_CR85","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.jacc.2003.05.003","volume":"42","author":"D Fraccarollo","year":"2003","unstructured":"Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2003.05.003.","journal-title":"J Am Coll Cardiol"},{"key":"2302_CR86","doi-asserted-by":"publisher","first-page":"H2241","DOI":"10.1152\/ajpheart.2001.281.5.H2241","volume":"281","author":"J Francis","year":"2001","unstructured":"Francis J, Weiss RM, Wei SG, Johnson AK, Beltz TG, Zimmerman K, et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol. 2001;281:H2241-2251. https:\/\/doi.org\/10.1152\/ajpheart.2001.281.5.H2241.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2302_CR87","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","volume":"47","author":"N Kobayashi","year":"2006","unstructured":"Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47:671\u20139. https:\/\/doi.org\/10.1161\/01.HYP.0000203148.42892.7a.","journal-title":"Hypertension"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02302-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02302-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02302-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:49:05Z","timestamp":1777002545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02302-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2302"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02302-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yueming Jiang, Jinbo hu, Xiaoyan Yi, Qifu Li, and Shumin Yang declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the data collected for the study, study protocol, and statistical code are available to approved persons through written agreements with the authors and the data partner with publication from Shumin Yang (email: 443068494@qq.com) or Qifu Li (e-mail: liqifu@yeah.net).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Y.J., J.H., and X.Y. conceived of and designed the study. Y.J., J.H., and S.Y. analyzed the data. Y.J. and J.H. drafted the manuscript. Y.J., J.H., X.Y., Q.L., and S.Y. revised and edited the manuscript. All authors had full access to and verified the data, and had final responsibility for the decision to submit for publication, Q.L. and J.H. obtained the funding.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}